Balancing between observational studies and randomized trials in prevention of coronary heart disease by estrogen replacement: HERS study was no revolution

References

• Stampfer M, Colditz G A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence. Prev Med 1991; 20: 47–63
   PubMed Web of Science ®Google Scholar
• Stampfer M J, Colditz G A, Willett W C, Manson J E, Rosner B, Speizer F E, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 1991; 325: 756–62
   PubMed Web of Science ®Google Scholar
• Grady D, Rubin S M, Petitti D B, Fox C S, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016–37
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer M J, Colditz G A, Willett W C, Manson J E, Joffe M, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769–75
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other consideration. Annu Rev Public Health 1998; 19: 55–72
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605–13
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Vittinghoff E, Bush T, Furberg C, Herrington D, et al. Hormone replacement therapy for secondary prevention of coronary heart disease. JAMA 1999; 281: 796–7
   PubMed Web of Science ®Google Scholar
• Andersson K, Pedersen A T, Mattsson L A, Milsom I. Swedish gynecologists' and general practitioners' views on the climacteric period: knowledge, attitudes and management strategies. Acta Obstet Gynecol Scand 1998; 77: 909–16
   PubMed Web of Science ®Google Scholar
• Hundrup Y A, Obel E B, Rasmussen D K., Philip J. Use of hormone replacement therapy among Danish nurses in 1993. Acta Obstet Gynecol Scand 2000; 79: 194–201
   PubMed Web of Science ®Google Scholar
• Sourander L, Rajala T, Räihä I, Mäkinen J, Erkkola R, Helenius H. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet 1998; 352: 1965–9
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer M J, Manson J E, Colditz G A, Willett W C, Rosner B, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453–61
   PubMed Web of Science ®Google Scholar
• Mikkola T, Viinikka L, Ylikorkala O. Estrogen and postmenopausal estrogen/progestin therapy: effect on endothelium-dependent prostacyclin, nitric oxide and endothelial. Eur J Obstet Gynecol Reprod Biol 1998; 79: 75–82
   PubMed Web of Science ®Google Scholar
• Bonduki C E, Lourenco D M, Baracat E, Haidar M, Noguti M AE, da Motta E LA, et al. Effect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women. Acta Obstet Gynecol Scand 1998; 77: 330–3
   PubMed Web of Science ®Google Scholar
• Cacciatore B, Paakkari I, Toivonen J, Tikkanen M J, Ylikorkala O. Randomized comparison of oral and transdermal hormone replacement on the carotid and uterine artery resistance to blood flow. Obstet Gynecol 1998; 92: 563–8
   PubMed Web of Science ®Google Scholar
• Raudaskoski T, Tomás C, Laatikainen T. Insulin sensitivity during postmenopausal hormone replacement with transdermal estradiol and intrauterine levonorgestrel. Acta Ob-stet Gynecol Scand 1999; 78: 540–5
   PubMed Web of Science ®Google Scholar
• Mendelsohn M E, Karas R H. The protective effect of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801–11
   PubMed Web of Science ®Google Scholar
• Tikkanen M J. Sex hormones. Lipoproteins in Health and Disease, J Shepherd, J Betteridge, R Illingworth. Arnold, London 1999; 967–84
   Google Scholar
• Mikkola T, Viinikka L, Ylikorkala O. Administration of transdermal estrogen without progestin increases the capacity of plasma and serum to stimulate prostacyclin production in human vascular endothelial cells. Fertil Steril 2000; 73: 72–4
   PubMed Web of Science ®Google Scholar
• Bush T L, Barrett-Connor E, Cowan L D, Criqui M H, Wallace R B, Suchindran C M. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75: 1102–9
   PubMed Web of Science ®Google Scholar
• Sullivan J M, van der Zwaag R, Hughes J P, Maddock V, Kroetz F W, Ramanathan K B, et al. Estrogen replacement and coronary artery disease: effect on survival in postmenopausal women. Arch Intern Med 1990; 150: 2557–62
   PubMed Web of Science ®Google Scholar
• Henderson B E, Paganini-Hill A, Ross R K. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991; 151: 75–8
   PubMed Web of Science ®Google Scholar
• Sullivan J M, El-Zeky F, van der Zwaag R, Ramanathan K B. Estrogen replacement therapy after coronary artery bypass surgery: effect on survival. J Am Coll Cardiol 1994; 23: 49A
   PubMed Web of Science ®Google Scholar
• Kim S C, O'Keefe J H, Ligon R W, Giorgi L V, Cavero P G, Hartzler G O. Estrogen improves long-term outcome after coronary angioplasty. Circulation 1995; 92: 674
   Web of Science ®Google Scholar
• Newton K M, LaCroix A Z, McKnight B, Knopp R H, Siscovick D S, Heckbert S R, et al. Estrogen replacement therapy and prognosis after first myocardial infarction. Am J Epidemiol 1997; 145: 269–77
   PubMed Web of Science ®Google Scholar
• O'Keefe J H, Jr., Kim S C, Hall R R, Cochran V C, Lawhorn S L, McCallister B D. Estrogen replacement therapy after coronary angioplasty in women. J Am Coll Cardiol 1997; 29: 1–5
   PubMed Web of Science ®Google Scholar
• Matthews K A, Kuller L H, Wing R R, Meilahn E N, Plantinga P. Prior to use of estrogen replacement therapy. Are users healthier than nonusers? Am J Epidemiol 1996; 143: 971–8
   PubMed Web of Science ®Google Scholar
• Rödström K, Bengtsson C, Lissner L, Björkelund C. Preexisting risk factor profiles in users and nonusers of hormone replacement therapy: prospective cohort study in Gothenburg, Sweden. BMJ 1999; 319: 890–3
   PubMed Web of Science ®Google Scholar
• Stadberg E, Mattsson L-Å, Milson I. Factors associated with climacteric symptoms and the use of hormone replacement therapy. Acta Obstet Gynecol Scand 2000; 79: 286–92
   PubMed Web of Science ®Google Scholar
• Beresford S AA, Weiss N S, Voigt L F. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progesteron therapy in postmenopausal women. Lancet 1997; 349: 458–61
   PubMed Web of Science ®Google Scholar
• Hillard T C, Siddle N C, Whitehead M I, Fraser D I, Pryse-Davies J. Continuous combined conjugated equine estrogen-progesteron therapy: Effects of medroxyprogesterone acetate and norethindrone acetate on bleeding patterns and endometrial histologic diagnosis. Am J Obstet Gynecol 1992; 167: 1–7
   PubMed Web of Science ®Google Scholar
• Adams M R, Kaplan J R, Marnuck S B, Koritnik D R, Parks J S, Wolfe M S, et al. Inhibition of coronary artery atherosclerosis by 17-ß-estradiol in ovariectomized monkeys -Lack of an effect of added progesterone. Arteriosclerosis 1990; 10: 1051–7
   PubMedGoogle Scholar
• Williams J K, Honore E K, Washburn S A, Clarkson T B. Effects of hormone replacement therapy on reactivity on artherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol 1994; 24: 1757–61
   PubMed Web of Science ®Google Scholar
• Adams M R, Register T C, Colden D L, Wagner J D, Williams J K. Medroxyprogesterone acetate antagonizes inhibitory effect of conjugated equine estrogens on coronary artery artherosclerosis. Arterioscler Thromb Vase Biol 1997; 17: 217–21
   PubMed Web of Science ®Google Scholar
• Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary spasm. Nat Med 1997; 3: 324–7
   PubMed Web of Science ®Google Scholar
• Suhonen S, Holmström T, Lähteenmäki P. Three-year following study of the use of a levonorgestrel-releasing intrauterine system in hormone replacement therapy. Acta Obstet Gynecol Scand 1997; 76: 145–50
   PubMed Web of Science ®Google Scholar
• Suvanto-Luukkonen E, Malinen H, Sundström H, Penttinen J, Kauppila A. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone. Acta Obstet Gynecol Scand 1998; 77: 758–63
   PubMed Web of Science ®Google Scholar
• Speroff L. The heart and estrogen/progestin replacement study (HERS). Maturitas 1998; 31: 9–14
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Wenger N K, Grady D, Mosca Z, Collins P, Kornitzer M, et al. Coronary heart disease in women, randomized clinical trials, HERS and RUTH. Maturitas 1998; 31: 1–7
   PubMed Web of Science ®Google Scholar
• Shlipak M G, Simon J A, Vittinghoff E, Lin F, Barrett-Connor E, Knopp R H, et al. Estrogen and progestin, lipoprotein. (a) and the risk of recurrent coronary heart disease events after menopause. JAMA 2000; 283: 1845–52
   PubMed Web of Science ®Google Scholar
• Petitti D B. Hormone replacement therapy and heart disease prevention. Experimentation tramps observation. JAMA 1998; 280: 650–2
   PubMed Web of Science ®Google Scholar